Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
| Revenue (TTM) | $2.58B |
| Gross Profit (TTM) | $1.79B |
| EBITDA | $-10.18M |
| Operating Margin | -12.80% |
| Return on Equity | -32.00% |
| Return on Assets | -2.21% |
| Revenue/Share (TTM) | $11.29 |
| Book Value | $1.39 |
| Price-to-Book | 17.32 |
| Price-to-Sales (TTM) | 2.35 |
| EV/Revenue | 2.451 |
| EV/EBITDA | 205.86 |
| Quarterly Earnings Growth (YoY) | -17.40% |
| Quarterly Revenue Growth (YoY) | 38.20% |
| Shares Outstanding | $224.94M |
| Float | $213.75M |
| % Insiders | 4.94% |
| % Institutions | 71.35% |
Volatility is currently expanding
Hims & Hers Health gears up for Q3 earnings, with weight loss demand, international expansion and subscriber growth fueling revenues despite margin pressures.
As part of the agreement, Hims said it won't compound GLP-1 medications like Zepbound in the future.
Hims & Hers stock rises after the company announces an agreement with Eli Lilly to offer the pharma giant's GLP-1s on its consumer platform.
Agreement gives patients a path to FDA-approved treatments at self-pay price through the Hims & Hers platform INDIANAPOLIS, Nov. 6, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Hims & Hers Health, Inc. (NYSE: HIMS) today announced an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). Through the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient without leaving the Hims & Hers platform.
Medicare for All is back on Wall Street's radar. Democrats won control of both the House and Senate in the Nov. 3, 2026, midterm elections.
Raul Shah explains how value investing can help investors navigate volatile markets, highlighting opportunities in Hims & Hers (HIMS), ServiceNow (NOW), and UnitedHealth (UNH). HIMS demonstrates rapid, sticky growth with rising average revenue per subscriber, strong insider ownership, and a robust balance sheet, despite high short interest and volatility.
New York, New York--(Newsfile Corp. - November 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline. SO WHAT: If you purchased Hims securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
LOS ANGELES, Nov. 02, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm notifies investors in Hims & Hers Health, Inc. (NYSE: HIMS) that a securities class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Hims common stock between August 4, 2025 and July 29, 2026, 2026, inclusive (the 'Class Period'). Find out if you qualify to recover your per-share losses by choosing to join the class action and submit your trade details . Investors who suffered financial losses have until November 2, 2026 to seek appointment as lead plaintiff. Shareholders should contact Lesley Portnoy via e-mail (Lesley@portnoylaw.com or call (310) 692-8883) or visit http://portnoylaw.com/hims-hers-health-inc to learn more information and discuss their legal rights.
LOS ANGELES--(BUSINESS WIRE)---- $HIMS--HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law.
Investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions Investors in Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HIMS and any ticker you trade — then tracks every position and per-strategy win rate.
